Abstract: Belzutifan (PT2977, MK-6482) is a first-in-class, second-generation small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α). It has emerged as a transformative targeted therapy for clear cell renal cell carcinoma (ccRCC), a malignancy fundamentally driven by the inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and subsequent HIF-2α accumulation. Belzutifan received regulatory approval for the treatment of VHL disease-associated tumors in 2021 and for previously treated advanced sporadic ccRCC in 2023. This comprehensive literature review synthesizes current evidence on belzutifan, detailing its pharmacological activity, molecular mechanism of action, structure-activity relationship, current clinical limitations including adverse events and resistance mechanisms, and future perspectives in combination therapies.
1. Introduction
Renal cell carcinoma (RCC) is a prevalent malignancy, with the clear cell histology (ccRCC) accounting for approximately 75% to 80% of all cases [2][5]. The pathogenesis of ccRCC is uniquely characterized by the alteration of the von Hippel-Lindau (VHL) tumor suppressor gene, which is inactivated via mutation, deletion, or epigenetic silencing in up to 90% of ccRCC tumors [1][2]. The loss of VHL function leads to the constitutive activation and accumulation of hypoxia-inducible factors (HIFs), particularly HIF-2α, which drives a pseudohypoxic response that promotes angiogenesis, metabolic reprogramming, and tumor proliferation [4][5]. For years, HIF-2α was considered an "undruggable" target [1]. However, the development of PT2977 (belzutifan, also known as MK-6482) marked a significant breakthrough. Belzutifan is a highly specific HIF-2α inhibitor that has demonstrated profound clinical efficacy, leading to its approval by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for VHL disease-associated tumors (including ccRCC, central nervous system hemangioblastomas, and pancreatic neuroendocrine tumors) and for advanced sporadic ccRCC following progression on immune checkpoint and anti-angiogenic therapies [1][2][9].
2. Pharmacological Activity
The clinical efficacy of belzutifan has been established through a series of robust clinical trials, predominantly the LITESPARK development program. In the phase II LITESPARK-004 trial involving patients with VHL disease-associated RCC, belzutifan monotherapy (120 mg daily) achieved an objective response rate (ORR) of 49% to 67.2%, with a 24-month progression-free survival (PFS) rate of 96% [2][4][9]. For sporadic advanced ccRCC, the phase I LITESPARK-001 trial demonstrated an ORR of 25% and a median PFS of 14.5 months in a heavily pretreated population [2][3]. The pivotal phase III LITESPARK-005 trial compared belzutifan to everolimus in patients with advanced ccRCC previously treated with PD-1/PD-L1 and VEGF inhibitors. Belzutifan significantly improved ORR (21.9% vs. 3.5%) and demonstrated superior PFS, leading to its FDA approval for this indication [2][3]. A recent meta-analysis of seven studies encompassing 715 patients reported a pooled ORR of 34%, a disease control rate (DCR) of 79%, and a median PFS of 8.8 months for belzutifan in advanced ccRCC [6].
Belzutifan is also highly active in combination regimens. The phase II LITESPARK-003 trial evaluating belzutifan plus the tyrosine kinase inhibitor (TKI) cabozantinib showed an ORR of 70% and a median PFS of 30.3 months in treatment-naive patients, and an ORR of 31% in previously treated patients [3][4]. Similarly, the KEYMAKER-U03B study demonstrated an ORR of 50% when belzutifan was combined with lenvatinib in a pretreated cohort [2][5].
3. Molecular Mechanism of Action
Under normoxic conditions, the VHL protein acts as the substrate-recognition component of an E3 ubiquitin ligase complex. It recognizes prolyl-hydroxylated HIF-α subunits (hydroxylated by oxygen-dependent prolyl hydroxylases) and targets them for rapid proteasomal degradation [1][2]. In the hypoxic tumor microenvironment, or when the VHL gene is mutated or deleted (as in ccRCC), this degradation process is halted. Consequently, HIF-2α accumulates and translocates into the nucleus, where it heterodimerizes with the aryl hydrocarbon receptor nuclear translocator (ARNT), also known as HIF-1β [1][2]. The resulting HIF-2α/HIF-1β transcription factor complex binds to hypoxia response elements (HREs) on the DNA, driving the transcription of downstream oncogenes such as vascular endothelial growth factor (VEGF), erythropoietin (EPO), and various glycolytic enzymes [2]. Belzutifan functions as a highly selective allosteric inhibitor that binds directly to HIF-2α. By doing so, it prevents the critical dimerization of HIF-2α with HIF-1β, thereby blocking the assembly of the functional transcription complex and halting the expression of tumor-promoting genes [2][3].
4. Structure-Activity Relationship (SAR)
The structural vulnerability of HIF-2α was identified when researchers discovered an internal, lipophilic cavity within its PAS-B (Per-ARNT-Sim) domain that was amenable to small-molecule ligand binding [1][2]. The first-in-class compound, PT2385, successfully bound to this pocket but exhibited suboptimal and highly variable pharmacokinetics [1][2]. Belzutifan (PT2977) was subsequently developed as a second-generation inhibitor with optimized pharmacological properties. Belzutifan binds to the PAS-B pocket of HIF-2α and induces allosteric changes that destabilize the HIF-2α/ARNT heterodimer. This allosteric inhibition is primarily mediated by interactions with the key residue M252 of HIF-2α, which is located near the dimer interface [3]. Compared to PT2385, belzutifan is approximately ten-fold more potent in xenograft models and provides more consistent and higher drug exposure, making it the superior clinical candidate [1][2].
5. Current Limitations
Despite its efficacy, belzutifan therapy is associated with specific limitations, primarily unique adverse events and the emergence of drug resistance. Because HIF-2α regulates erythropoiesis and the hypoxic ventilatory response, belzutifan induces distinct on-target toxicities. Anemia is the most common adverse event, occurring in over 84% of patients (with grade 3 or higher in ~28%), driven by the suppression of HIF-2α-mediated EPO production [1][2]. Hypoxia is another significant toxicity, observed in approximately 16% of patients, which can necessitate dose reductions, supplemental oxygen, or treatment discontinuation [1][9].
Acquired resistance to belzutifan is a growing clinical challenge. Molecular analyses of resistant tumors have identified "gatekeeper" mutations within the binding pocket. The most prominent is the G323E mutation in the EPAS1 gene (which encodes HIF-2α). This mutation alters the PAS-B binding site, sterically hindering belzutifan from binding while preserving the protein's ability to dimerize with HIF-1β [2][4][5]. Additionally, an F446L mutation in HIF-1β has been identified, which enhances its binding affinity for HIF-2α, overcoming the allosteric blockade [2]. Other proposed resistance mechanisms include a compensatory shift toward HIF-1α dependency (characterized by elevated HIF1A expression), elevation of phosphoglycerate dehydrogenase (PHGDH), and increased expression of FK506 binding protein 10 (FKB10) [2][5].
6. Future Perspectives
The future of belzutifan in ccRCC management lies in its integration into earlier lines of therapy and rational combination strategies to enhance efficacy and overcome resistance. Several phase III trials are currently underway. LITESPARK-011 is comparing belzutifan plus lenvatinib against cabozantinib in the second-line setting [2][5]. In the front-line setting, LITESPARK-012 is evaluating the addition of belzutifan to the standard-of-care doublet of pembrolizumab and lenvatinib [2]. Furthermore, LITESPARK-022 is investigating belzutifan plus pembrolizumab as an adjuvant therapy for high-risk ccRCC post-nephrectomy [2][3].
To combat resistance, novel combinations are being explored based on synthetic lethality and metabolic vulnerabilities. For instance, the combination of belzutifan with CDK4/6 inhibitors (e.g., palbociclib) is being tested in LITESPARK-024, based on preclinical synergy between VHL loss and CDK4/6 inhibition [2][5]. Additionally, early-phase trials are investigating belzutifan alongside HC-7366, an activator of the GCN2 kinase stress response pathway, and with Hsp70 inhibitors, which have shown preclinical promise in overcoming G323E-mediated resistance [2][5]. The identification of predictive biomarkers, such as baseline EPO levels or specific gene expression signatures, will be crucial for optimizing patient selection in the future [2].
